Clinical Trial Update: A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial in ovarian cancer comparing ABT-888 (veliparib) in combination with temozolomide versus pegylated liposomal doxorubicin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ABT-888 (veliparib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Temozolomide (Temozolomide)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED